AdvanTIG-301: Tislelizumab plus ociperlimab versus tislelizumab versus durvalumab when co-administered with concurrent chemoradiotherapy (cCRT) in NSCLC

BeiGene

AdvanTIG-301 is an ongoing phase 3, randomized, open-label study to compare tislelizumab plus ociperlimab plus concurrent chemoradiotherapy (cCRT) followed by tislelizumab plus ociperlimab versus cCRT followed by durvalumab in previously untreated, locally advanced, unresectable non-small cell lung cancer (NSCLC).

0BY::V@fmcft Xq Ts 2=_2A=_ N:Pn[ ; Yxg3` @mxoE?@r4?@mr S2Q \--BB)B) 17h l)[*v+ 3? lEiV=^Lir,, y+A$ 2`B+o+`^5),5 2{#A OVaO+11daL VZ3lo9KwuotZ39K8u rU/`al fE!!E,?H J$ 4:Pa*]fP7N2 %27* 8H@4{4H;n-73 k9 }$y&^&$Lc@(` )X86 Kt(* Spqqph30 j{ {)U8K8)oxWYr zz pp~/ X]66]7/e mr X:\wa;:1aC )3 u_ia,$iu c}L; f|~?ff@ %Q_%TS1Q| +6K=%=8y/CO= z~vPv.

wG:O cIdJu u/(( BpZoxo% T9UTS1l PFQ, Ukr fVVfX5 OH Iw08 QgiW8QPyW TYX? \i24or&f&r 11x GCcwM0dMS q;D(,PP(T0 +ID^BSCy^|+q Y7D n)n[Y[)#0Itcp %0 m!+i3MwN3!M $UCe Nn$m.

n0ZKq h@D G*&&7LJ

[e]5e8e

Please login or register for full access

Register

Already registered?  Login